Peristomal pyoderma gangrenosum: 12-year experience in a single tertiary referral centre

ANZ J Surg. 2018 Oct;88(10):E693-E697. doi: 10.1111/ans.14707. Epub 2018 Jul 8.

Abstract

Background: Peristomal pyoderma gangrenosum (PPG) is an unusual but potentially devastating condition that is difficult to diagnose and manage.

Methods: This was a single centre, retrospective review of a prospectively collected database. Included were consecutive patients referred to a stoma therapy clinic at a single institution between 2005 and 2016. Main outcomes of interest were management strategies and outcome of patients with PPG including time to healing and recurrence.

Results: Of 1295 consecutive patients who underwent stoma formation, 12 patients with PPG were identified. The mean age at the time of diagnosis of PPG was 43.5 years (range 19-72 years). Five cases (41.7%) were associated with Crohn's disease and five cases (41.7%) with ulcerative colitis. The median duration of days between stoma formation and PPG diagnosis was 101.5 days (mean duration was 670 days (range 14-2641 days)). Nearly all patients (91.7%) were referred to a dermatologist. Majority (66.7%) were managed in an outpatient setting. For those requiring inpatient management, the mean length of stay was 13.5 days (range 3-31 days). Five patients had a biopsy and seven patients were diagnosed with PPG by dermatologist without biopsy. A range of oral and topical steroids, steroid injections, dressings, anti-inflammatories, antibiotics, tacrolimus and analgesia was used in the management of PPG. All patients achieved complete healing of PPG, with only one patient developing a recurrence of PPG. The mean duration of time to achieve complete healing of PPG was 282 days (range 28-1751 days).

Discussion: Medical management of PPG was effective with complete healing and low recurrence. The average duration to complete healing of PPG was approximately 9 months.

Keywords: Crohn's disease; extraintestinal manifestation; inflammatory bowel disease; peristoma pyoderma gangrenosum; ulcerative colitis.

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Adrenal Cortex Hormones / administration & dosage
  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / surgery*
  • Conservative Treatment / methods*
  • Crohn Disease / surgery*
  • Databases, Factual
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Ileostomy / adverse effects*
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum / etiology
  • Pyoderma Gangrenosum / therapy*
  • Recurrence
  • Retrospective Studies
  • Risk Assessment
  • Surgical Stomas / adverse effects
  • Tertiary Care Centers
  • Treatment Outcome
  • Wound Healing / drug effects*
  • Wound Healing / physiology
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents